Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

被引：0
|
作者：
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
机构：
[1] University of Alabama at Birmingham,
[2] Comprehensive Cancer Center,undefined
[3] Oregon Health & Science University,undefined
[4] University of Texas Southwestern,undefined
[5] Division of Hematology and Oncology,undefined
[6] University of Wisconsin Carbone Cancer Center,undefined
[7] Pfizer Inc,undefined
[8] Global Research and Development,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Sunitinib; Docetaxel; Solid tumors; Phase I; NSCLC; Antiangiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 680
页数：11
相关论文
共 50 条
  • [31] A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
    Raez, Luis E.
    Papadopoulos, Kyriakos
    Ricart, Alejandro D.
    Chiorean, E. Gabriella
    DiPaola, Robert S.
    Stein, Mark N.
    Lima, Caio M. Rocha
    Schlesselman, James J.
    Tolba, Khaled
    Langmuir, Virginia K.
    Kroll, Stewart
    Jung, Donald T.
    Kurtoglu, Metin
    Rosenblatt, Joseph
    Lampidis, Theodore J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 523 - 530
  • [32] Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
    Edward Sausville
    Patricia LoRusso
    Michael Carducci
    Judith Carter
    Mary F. Quinn
    Lisa Malburg
    Nilofer Azad
    David Cosgrove
    Richard Knight
    Peter Barker
    Sonya Zabludoff
    Felix Agbo
    Patricia Oakes
    Adrian Senderowicz
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 539 - 549
  • [33] Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma
    Satomura, Hitoshi
    Nakajima, Masanobu
    Sasaki, Kinro
    Yamaguchi, Satoru
    Domeki, Yasushi
    Takahashi, Masakazu
    Muroi, Hiroto
    Kubo, Tsukasa
    Kikuchi, Maiko
    Otomo, Haruka
    Ihara, Keisuke
    Kato, Hiroyuki
    INTERNATIONAL SURGERY, 2015, 100 (06) : 1153 - 1158
  • [34] Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
    Sausville, Edward
    LoRusso, Patricia
    Carducci, Michael
    Carter, Judith
    Quinn, Mary F.
    Malburg, Lisa
    Azad, Nilofer
    Cosgrove, David
    Knight, Richard
    Barker, Peter
    Zabludoff, Sonya
    Agbo, Felix
    Oakes, Patricia
    Senderowicz, Adrian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 539 - 549
  • [35] A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
    Mavroudis, D
    Pappas, P
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Vardakis, N
    Nikolaidou, M
    Samonis, G
    Marselos, M
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 304 - 312
  • [36] A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma
    Tracy Murray Stewart
    Daniel Von Hoff
    Michael Fitzgerald
    Laurence J. Marton
    Carlos H. Roberto Becerra
    Thomas E. Boyd
    Paul R. Conkling
    Lawrence E. Garbo
    Robert M. Jotte
    Donald A. Richards
    David A. Smith
    Joe J. Stephenson
    Nicholas J. Vogelzang
    Hillary H. Wu
    Robert A. Casero
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 135 - 144
  • [37] Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas
    Aspeslagh, Sandrine
    Stein, Mark
    Bahleda, Rastilav
    Hollebecque, Antoine
    Salles, Gilles
    Gyan, Emmanuel
    Fudio, Salvador
    Extremera, Sonia
    Alfaro, Vicente
    Soto-Matos, Arturo
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2017, 28 (03) : 341 - 349
  • [38] A dose escalation study of weekly docetaxel in patients with advanced solid tumors
    Ch. Kouroussis
    S. Agelaki
    D. Mavroudis
    J. Souglakos
    S. Kakolyris
    K. Kalbakis
    N. Vardakis
    D. Reppa
    D. Hatzidaki
    G. Samonis
    V. Georgoulias
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 488 - 492
  • [39] A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma
    Murray Stewart, Tracy
    Von Hoff, Daniel
    Fitzgerald, Michael
    Marton, Laurence J.
    Becerra, Carlos H. Roberto
    Boyd, Thomas E.
    Conkling, Paul R.
    Garbo, Lawrence E.
    Jotte, Robert M.
    Richards, Donald A.
    Smith, David A.
    Stephenson, Joe J., Jr.
    Vogelzang, Nicholas J.
    Wu, Hillary H.
    Casero, Robert A., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 135 - 144
  • [40] A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours
    Atrafi, Florence
    Dumez, Herlinde
    Mathijssen, Ron H. J.
    van Oordt, Catharine W. Menke van der Houven
    Rijcken, Cristianne J. F.
    Hanssen, Rob
    Eskens, Ferry A. L. M.
    Schoffski, Patrick
    JOURNAL OF CONTROLLED RELEASE, 2020, 325 (325) : 191 - 197
12345